6 Cedarbrook Drive, Cranbury, NJ 08512, USA cfpc.jstar@jstar-research.com

Technical Program

October 13-14, 2022; Princeton, NJ, USA

Workshop: CMC Development Strategies
  • Combined In-Silico & Experimental Approach for Solid Form Screen & Selection
        Drs. Yuriy Abramov and Shanming Kuang, J-Star Research
  • Enabling Technologies for Tox/FIH Formulation
        Dr. San Kiang, J-Star Research
  • Simulation Aided Process/Product Development, Scale-Up, Tech-Transfer, and Regulatory Submission
        Dr. Nima Yazdanpanah, Procegence
  • Session 1: Smarter Solid Form & Pre-Formulation Studies
  • Reducing or Managing Complexity- New Realities With Emerging Chemical Space for Small Molecule Developability
        Dr. Ahmad Sheikh, AbbVie
  • Five Degrees of Separation: Characterization and Temperature Stability Profiles for the Polymorphs of PD-0118057 (Molecule XXIII)
        Mr. Brian Samas, Pfizer
  • Novel Analytical Methods and Insights into Amorphous Solid Dispersions
        Dr. Simon Bates, Rigaku
  • Digitally Enabled Workflows: Accelerating the Molecule to Medicine Journey
        Dr. Bob Docherty , West View House Consulting
  • Session 2: Physical Property Based Crystallization Process Dev
  • A New Stereo-Purification Approach Enabled by Continuous Flow-Crystallization
        Dr. Michal Achmatowicz, Mirati Therapeutics
  • Simulation Aided Solvent Selection for Robust Impurity Rejection By Crystallization
         Dr. Yuriy Abramov, J-Star Research
  • A Digital Mechanistic Workflow for Predicting Solvent-Mediated Crystal Morphology
        Prof. Kevin Roberts, University of Leeds
  • Intelligent Cloud-Based Algorithms For Reducing Risk in Crystallization Process Development
        Dr. Mike Bellucci, XtalPi
  • Session 3: Particle Engineering & DS-DP Co-Processing
  • Control, Is It Achievable in Amorphous or Poorly Crystalline Peptide Isolations?
        Dr. Jeremy M. Merritt, Eli Lilly
  • Particle Engineering by Spray Drying: Process Dev., Scale-Up, and Technology Transfer
        Dr. Nima Yazdanpanah, Procegence
  • Amorphous or Crystalline? Using Next Generation PAT to Track API Particle Attributes for Enhanced Downstream Processability
        Richard Becker, BlazeMetrics
  • Topical Panel Discussions
  • Challenges and Solutions of Developing Amorphous Solids as Drug Substance
  • Bottlenecks and Breakthroughs of Computational Solutions for Drug Substance & Product Development
  • Early Formulation Challenges and Solutions – Discovery to Phase I
  • RSS
    Follow by Email
    LinkedIn
    Share